Pipeline Therapeutics Completes $80 Million Series C Financing
February 5, 2021
Ekspertenes biotekfavoritter i urolige tider, e24.no
January 26, 2021
Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS- 248 in patients with systemic sclerosis
January 21, 2021
Abliva appoints Ellen Donnelly as new CEO as they enter a new development stage
January 11, 2021
Oncoinvent Announces Advancement of Radspherin® to Final Dose Level Cohort in Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients
January 3, 2021
Helsestartups får stryk på mangfold, e24.no
December 1, 2020
Galecto Publishes GB0139 Phase 2a (IPF) Results in European Respiratory Journal
November 17, 2020
Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan
November 10, 2020
Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021
October 29, 2020
Oncoinvent Advances Radspherin® to Third Dose Level in Ongoing Phase 1 Clinical Trial
October 28, 2020
Galecto Announces Pricing of Initial Public Offering
October 22, 2020
Neuro Event Labs Receives FDA Breakthrough Device Designation for Nelli®
October 8, 2020
Abliva doses the first patient in its KL1333 Phase Ia/b clinical study
September 25, 2020
Hadean Ventures invest in Galecto`s $64 million round equity financing
September 14, 2020
Ingrid Teigland Akay included in Business Insider’s list of 100 People Transforming Business in Europe.
September 9, 2020
Abliva intends to start a pivotal KL1333 study second half 2021
September 4, 2020
Oncoinvent Advances Radspherin[®] to Second Dose Level in Ongoing Phase 1 Clinical Trial
August 14, 2020
Pewin Member Highlight 2020: Ingrid Teigland Akay
July 28, 2020
Abliva receives positive FDA feedback on its KL1333 development plan
July 28, 2020
Pipeline Therapeutics Initiates Phase 1/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss
July 28, 2020
Gesynta raises SEK 190 million in round led by Hadean Ventures to accelerate development of first-in-class mPGES-1 inhibitor GS-248 for systemic sclerosis
June 18, 2020
€1.9M EU funding takes Nelli® available for all epilepsy patients
June 15, 2020
Abliva completes the directed issue of MSEK 20 to Hadean Ventures
June 11, 2020
Oncoinvent Announces Dosing of First Patient with Radspherin® in a Second Phase 1 Clinical Trial
June 2, 2020
Oncoinvent Announces Dosing of First Patient with Radspherin® in Phase 1 Clinical Trial
May 26, 2020
MSD to Acquire Themis
April 22, 2020
NeuroVive makes a MSEK 20 directed share issue to leading Nordic life science investor Hadean Ventures
April 16, 2020
Varsler massive coronakjøp, Finansavisen
April 9, 2020
Neuro Event Labs Oy closes EUR 3.9m Series A investment round from Hadean Ventures, SHS Gesellschaft für Beteiligungsmanagement and Maki.vc
March 20, 2020
Themis and Institut Pasteur Join Coronavirus Vaccine Hunt
December 18, 2019
Pipeline Therapeutics Completes $30 Million Series B Financing
November 27, 2019
Hadean Ventures receives Rising Star Award at the 10th edition of the Private Equity Exchange & Awards 2019 in Paris
September 18, 2019
Hadean Ventures invests in Themis Bioscience GmbH EUR 40m Series D Financing round
June 11, 2019
Hadean Ventures leads 40 million SEK (€3.7 million) investment round into SAGA to advance ultrasensitive cancer liquid biopsies
March 26, 2019
Hadean Ventures’ Ingrid Teigland Akay receives Investor of the Year award at the SHE conference
March 26, 2019
Level 20 selects Ingrid Teigland Akay as one of nine Inspiring Women in European Private Equity
November 6, 2018
Hadean Ventures is pleased to announce the appointment of Roger Franklin PhD as Partner to be based in Hadean’s Stockholm office at the Karolinska Institute Science Park.
July 13, 2018
Hadean Ventures, SINTEF Venture V and Investinor invest in Nisonic AS to develop advanced ultrasound technology for neurological conditions.
June 16, 2018
Investorview: Plugging knowledge gaps to accelerate life science start-up development
May 22, 2018
Hadean Ventures today announces an investment in AttgeNO AB, a Swedish pharmaceutical company developing treatments for acute life-threatening conditions.
December 18, 2017
Hadean Ventures launches new fund to leverage untapped potential of European life science startups
